Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Technology Industry News EQT Private Equity to acquire Avetta to bolster global supply chain resilience EQT Private Equity, under its EQT X fund, announced today a significant strategic acquisition, taking over Avetta from… byPallavi MadhirajuApril 3, 2024